Comparison of the Eight Different Treatment Regimens for the Hospitalized Patients with COVID-19: A Retrospective Cohort Study

Mohammad Haji Aghajani; Elham Porheidar; Omid Moradi; asma Pourhosseingoli; Nilofar Taherpour; Armineh Barootkoob; Rezvan Hassanpour; Elmira Agah; seyed vahid mosavi; Mohammad Sistanizad

doi:10.5812/jcma-151632

Journal of Cellular & Molecular Anesthesia

Journal Information Editors & Boards Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement New Publisher Announcement Reviewer and AE Registration Form Contact Us Support

APC

Authors Guide Submit Manuscript

https://doi.org/10.22037/jcma.v6i4.35553

Comparison of the Eight Different Treatment Regimens for the Hospitalized Patients with COVID-19: A Retrospective Cohort Study

Author(s):

Mohammad Haji Aghajani¹,

Elham Porheidar²,

Omid Moradi³,

asma Pourhosseingoli¹,

Nilofar Taherpour⁴,

Armineh Barootkoob³,

Rezvan Hassanpour³,

Elmira Agah^{5, 6, 7},

seyed vahid mosavi^{8, 9},

Mohammad Sistanizad

^{3, 4,*}

1Prevention of Cardiovascular Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4Prevention of Cardiovascular Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

5Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

6Students’ Scientific Research Center, Tehran University of Medical Sciences,Tehran, Iran.

7Neuroimmunology Research Association (NIRA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

8Students’ Scientific Research Center, Tehran University of Medical Sciences,Tehran, Iran

9Neuroimmunology Research Association (NIRA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

Journal of Cellular & Molecular Anesthesia:Vol. 6, issue 4; e151632

Published online:Aug 07, 2021

Article type:Research Article

How to Cite:Mohammad Haji AghajaniElham PorheidarOmid Moradiasma PourhosseingoliNilofar TaherpourArmineh BarootkoobRezvan HassanpourElmira Agahseyed vahid mosaviMohammad Sistanizadet al.Comparison of the Eight Different Treatment Regimens for the Hospitalized Patients with COVID-19: A Retrospective Cohort Study.J Cell Mol Anesth.6(4):e151632.https://doi.org/10.22037/jcma.v6i4.35553.

Abstract

Background: Coronavirus disease 2019 (COVID -19) characterized by a mild to severe respiratory illness, has been affecting the world since late 2019 and leading to an increase in hospitalizations and deaths. There is still no specific highly effective treatment for this disease. This study aimed to compare the efficacy of the eight different treatment regimens for the hospitalized patients with COVID-19.

Methods: This retrospective cohort study was conducted on the hospitalized patients who had laboratory-confirmed COVID-19 by a real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) of nasopharyngeal samples.

Results: Among all patients hospitalized with COVID-19 between March to September 2020, 861 patients were included in the study. This study indicated that treatment protocols included either remdesivir or favipiravir were superior to hydroxychloroquine in reducing the risk of in-hospital mortality of the patients with confirmed COVID-19, especially in critical patients defined as those who were ICU admitted or under mechanical ventilation (HR, 0.43; 95% CI, 0.23 to 0.82; P=0.011 and HR, 0.45; 95% CI, 0.22 to 0.90; P=0.024, respectively). Whereas receiving lopinavir/ritonavir in combination with either hydroxychloroquine plus interferon β and corticosteroids (HR, 1.85; 95% CI, 1.17 to 2.94; P=0.009), hydroxychloroquine plus interferon β (HR, 1.66; 95% CI, 1.01 to 2.74; P=0.046), or interferon β (HR, 1.80; 95% CI, 1.12 to 2.89; P=0.015) was associated with a significant increase in this risk.

Conclusion: Our findings indicate that using remdesivir and favipiravir in combination with interferon β and corticosteroids might be beneficial in hospitalized patients with COVID-19, especially in the critical ones.

Keywords

Coronavirus disease 2019

Critically ill, In-hospital mortality

Treatment regimens

References

1.
References are in the PDF file of the article.

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

CrossRef 0

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Mohammad Haji Aghajani:[PubMed][Scholar]
Elham Porheidar:[PubMed][Scholar]
Omid Moradi:[PubMed][Scholar]
asma Pourhosseingoli:[PubMed][Scholar]
Nilofar Taherpour:[PubMed][Scholar]
Armineh Barootkoob:[PubMed][Scholar]
Rezvan Hassanpour:[PubMed][Scholar]
Elmira Agah:[PubMed][Scholar]
seyed vahid mosavi:[PubMed][Scholar]
Mohammad Sistanizad:[PubMed][Scholar]